학술논문
25P Platinum-based chemotherapy (PCT) addition to first-line PD-1/PD-L1 inhibitors (ICI) prevent hyperprogressive disease (HPD) in non-small cell lung cancer (NSCLC) patients (pts) by reducing circulating immature neutrophils
Document Type
Abstract
Author
Source
In Immuno-Oncology and Technology December 2022 16 Supplement 1
Subject
Language
ISSN
2590-0188